跳至主要内容
临床试验/NCT02802345
NCT02802345已完成3 期

INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment

Boehringer Ingelheim85 个研究点 分布在 8 个国家目标入组 274 人开始时间: 2016年6月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
274
试验地点
85
主要终点
Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score at Week 12

研究概览

简要总结

To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Nintedanib + placebo matching sildenafil

Experimental

干预措施: Nintedanib (Drug)

Nintedanib + placebo matching sildenafil

Experimental

干预措施: Placebo (Drug)

Nintedanib + Sildenafil

Active Comparator

干预措施: Nintedanib (Drug)

Nintedanib + Sildenafil

Active Comparator

干预措施: Sildenafil (Drug)

结局指标

主要结局

Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score at Week 12

时间窗: Baseline and week 12

The SGRQ is a 50-item questionnaire developed to measure health status (quality of life). Scores are calculated for three domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. A minimum change in score of 4 units was established as clinically relevant after patient and clinician testing. Scores range from 0 to 100, with higher scores indicating more limitations. The mean and standard error presented are actually adjusted mean for change from baseline and its standard error.

次要结局

  • Change From Baseline in Dyspnoea Using UCSD SOBQ at Week 24(Baseline and week 24)
  • Change From Baseline in Dyspnoea Using the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) at Week 12(Baseline and week 12)
  • Percentage of Patients With On-treatment Serious Adverse Events (SAE) From Baseline to Week 24(Baseline and week 24)
  • Change From Baseline in SGRQ Total Score at Week 24(Baseline and week 24)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (85)

Loading locations...

相似试验